Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
$82.45
$0.80(1.09%)
At close: 4:00 PM EST
$82.45
$0.80(1.09%)
Day’s Range― - ―
52-Week Range$64.89 - $87.09
Previous CloseN/A
Volume821.68K
Average Volume (3M)5.06M
Market Cap
$48.41B
Enterprise Value$43.15B
Total Cash (Recent Filing)$4.06B
Total Debt (Recent Filing)$702.60M
Price to Earnings (P/E)35.1
Beta0.79
Next Earnings
Feb 04, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding587,100,000
10 Day Avg. Volume6,745,496
30 Day Avg. Volume5,056,805
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue7.59
Enterprise Value/Gross Profit9.62
Enterprise Value/Ebitda24.20
Forecast
1Y Price Target
$92.62Price Target Upside12.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
Bulls Say, Bears Say
Bulls Say
Clinical Data And ApprovalsThe presentation of successful mitral replacement data, expected to lead to FDA approval, completes the company's 'toolbox' for mitral market opportunities.
Financial PerformanceThe company's Q3 revenue and EPS soundly beat Street forecasts, showcasing strong financial performance.
Revenue Growth GuidanceEdwards Lifesciences raised its 2025 revenue growth guidance to the high end of its range, supported by increased TAVR sales guidance.
Bears Say
Coverage UncertaintyTiming for CMS coverage is still uncertain, especially with government shutdown.
Long-term Outcome ConcernsThe performance of TAVR in the P3 trial continues to get worse, and the long-term outcomes should still be monitored and questioned.
Mortality RatesDeath from any cause was numerically higher in the TAVR group at 19.4% compared to 14.9% in the surgery group.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $64.89 and its highest was $87.09 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $48.41B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Feb 04, 2026 which is in 91 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Oct 30, 2025. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.596 by $0.074.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.62.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 587,100,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.67 in its last earnings report, beating expectations of $0.596. Following the earnings report the stock price went down -1.234%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$92.62 (12.33% Upside)
$92.62 (12.33% Upside)
Blogger Sentiment
Bullish
EW Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation is a global leader in heart valve replacement and repair therapies, as well as hemodynamic monitoring. The company specializes in innovative medical devices and technologies that address the needs of patients with structural heart disease and critical care monitoring. Edwards Lifesciences operates primarily in two sectors: surgical heart valves and transcatheter heart valves, delivering advanced solutions that provide improved outcomes for patients with cardiovascular conditions. Core products include the SAPIEN valve system for transcatheter aortic valve replacement and a range of monitoring solutions for critically ill patients.
EW Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Edwards Lifesciences reported strong quarterly performance with significant sales growth across multiple segments, increased full-year guidance, and positive clinical data presentations. However, there were some concerns about declining gross profit margins and upcoming changes in financial leadership.View all EW earnings summariesEW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
EW Stock 12 Month Forecast
Average Price Target
$92.62
▲(12.33% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
22.56% Mutual Funds
0.95% Other Institutional Investors
52.19% Public Companies and
Individual Investors